Chicago, Illinois-based CME Group Inc. (CME) is a global financial derivatives marketplace operator that runs exchanges for trading futures, options, cash, and over-the-counter products. With a market capitalization of approximately $113.8 billion, the company offers benchmark contracts across major asset classes, including interest rates, equities, foreign exchange, energy, agriculture, and metals, while providing market data and risk management solutions to institutional and individual clients worldwide.
Shares of the world’s leading derivatives marketplace have outperformed the broader market over the past year. CME has advanced 12% during this period, compared with a nearly 10.1% gain in the S&P 500 Index ($SPX). The stock has maintained its momentum in 2026, rising 17% year-to-date, while the index has gained 8.3% over the same period.
CME has also outperformed the broader financial services sector, as represented by the iShares U.S. Broker-Dealers & Securities Exchanges ETF (IAI), which has gained 4.2% over the past year and risen marginally year-to-date.
On Oct. 21, 2026, CME Group Inc. reported its Q3 2026 results, with revenue increasing 13% year over year to a record $1.74 billion. Adjusted diluted EPS rose 12.7% to $3.02, while adjusted net income increased 10.8% to $1.08 billion. The growth was driven by higher trading activity, with average daily volume climbing 16.3% to a third-quarter record of 29.4 million contracts. Clearing and transaction fee revenue increased 12% to $1.38 billion, while market data revenue rose 20% to a record $243 million.
During the quarter, CME Group returned nearly $1 billion to shareholders, including $524 million in share repurchases and $465 million in regular quarterly dividends. The company also highlighted progress in its cloud migration, new product launches, and record average daily capital efficiencies of $100 billion. The earnings release did not include updated full-year guidance. Following the announcement, CME shares rose 3.5% in the next trading session.
For the current fiscal year ending in December 2026, analysts expect CME’s diluted EPS to increase 10.3% to $12.35. The company has beaten consensus EPS estimates in three of the past four quarters while missing expectations in one.
Among the 19 analysts covering CME stock, the consensus rating is “Moderate Buy.” This comprises seven “Strong Buy,” three “Moderate Buy,” seven “Hold,” one “Moderate Sell,” and one “Strong Sell” recommendation.
The analyst configuration is more bullish than it was a month ago, when there were six “Strong Buy” recommendations.
On Oct. 23, 2026, Goldman Sachs analyst Alexander Blostein maintained a “Sell” rating on CME Group and raised the price target to $271 from $254.
CME’s current share price of $319.37 is above the mean price target of $317.35. However, the Street-high price target of $367 suggests an upside potential of 14.9%.